From the FDA Drug Label
7 DRUG INTERACTIONS
7.1 Concomitant Use with Insulin or an Insulin Secretagogue (e.g., Sulfonylurea) ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia [see Warnings and Precautions (5.7)]. 7. 2 Oral Medications ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected [see Use in Specific Populations (8. 3) and Clinical Pharmacology (12.2,12.3)].
The medications that interact with Zepbound are:
- Insulin: Zepbound lowers blood glucose, so the dose of concomitantly administered insulin should be reduced to minimize the risk of hypoglycemia.
- Insulin secretagogues (e.g., Sulfonylurea): similar to insulin, the dose should be reduced when used with Zepbound.
- Oral medications: Zepbound delays gastric emptying, which may impact the absorption of oral medications, especially those with a narrow therapeutic index (e.g., warfarin).
- Oral hormonal contraceptives: patients should switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation 1.
From the Research
Zepbound (generic name) can interact with several medications, requiring careful management to minimize the risk of adverse effects and optimize patient outcomes, particularly in terms of morbidity, mortality, and quality of life. The most significant interactions occur with medications that are substrates, inhibitors, or inducers of the cytochrome P450 enzyme system, specifically CYP3A4, as seen in studies such as 2.
Key Interactions to Consider
- Insulin and other diabetes medications, which can increase the risk of hypoglycemia (low blood sugar) 3
- Oral medications that require rapid gastrointestinal absorption, such as oral contraceptives and antibiotics, which should be taken at least one hour before Zepbound to minimize interaction effects
- Medications with narrow therapeutic indices like warfarin, digoxin, and certain anti-seizure medications, which may require dose adjustments when co-administered with Zepbound
Management of Interactions
- Patients should inform their healthcare provider about all medications they're taking, including over-the-counter drugs and supplements, to facilitate the identification of potential interactions
- Dose adjustments of concurrent medications may be necessary when starting, increasing, or discontinuing Zepbound, considering its long half-life and potential for persistent effects
- Healthcare providers should be aware of the potential for drug-drug interactions and take steps to prevent them, as highlighted in studies such as 4, to reduce morbidity and mortality in patients receiving polypharmacy.
Prioritizing Patient Safety
Given the potential for significant interactions, it is crucial to prioritize patient safety by carefully evaluating the medication regimen and making adjustments as necessary to minimize the risk of adverse effects. This approach is supported by recent studies, such as 3, which emphasize the importance of understanding and managing common drug interactions to optimize patient outcomes.